ABIVAX Société Anonyme (ABVX.PA)
EUR 5.24
(-0.19%)
EUR 5.24
(-0.19%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 3.91 Million EUR | -13.25% |
| 2022 | 4.51 Million EUR | 3891.6% |
| 2021 | -119 Thousand EUR | -128.85% |
| 2020 | -52 Thousand EUR | 40.23% |
| 2019 | -87 Thousand EUR | 99.4% |
| 2018 | -14.56 Million EUR | -43.94% |
| 2017 | -10.11 Million EUR | 30.21% |
| 2016 | -14.49 Million EUR | 0.21% |
| 2015 | -14.52 Million EUR | -6521.05% |
| 2014 | -219.36 Thousand EUR | -154.73% |
| 2013 | -86.11 Thousand EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 6.21 Million EUR | 0.0% |
| 2023 Q2 | 1.91 Million EUR | 0.0% |
| 2023 FY | 3.91 Million EUR | -13.25% |
| 2023 Q4 | 1.86 Million EUR | 0.0% |
| 2022 Q2 | 2.18 Million EUR | 0.0% |
| 2022 Q4 | 2.21 Million EUR | 0.0% |
| 2022 FY | 4.51 Million EUR | 3891.6% |
| 2021 FY | -119 Thousand EUR | -128.85% |
| 2021 Q2 | -32 Thousand EUR | 0.0% |
| 2021 Q4 | -124 Thousand EUR | 0.0% |
| 2020 Q2 | -33 Thousand EUR | 0.0% |
| 2020 Q4 | -19 Thousand EUR | 0.0% |
| 2020 FY | -52 Thousand EUR | 40.23% |
| 2019 Q2 | -5000.00 EUR | 0.0% |
| 2019 FY | -87 Thousand EUR | 99.4% |
| 2019 Q4 | -82 Thousand EUR | 0.0% |
| 2018 FY | -14.56 Million EUR | -43.94% |
| 2018 Q4 | -8.17 Million EUR | 0.0% |
| 2018 Q2 | -6.38 Million EUR | 0.0% |
| 2017 FY | -10.11 Million EUR | 30.21% |
| 2017 Q4 | -4.74 Million EUR | 0.0% |
| 2017 Q2 | -5.37 Million EUR | 0.0% |
| 2016 FY | -14.49 Million EUR | 0.21% |
| 2016 Q2 | -8.61 Million EUR | 0.0% |
| 2016 Q4 | -5.87 Million EUR | 0.0% |
| 2015 Q2 | -6.49 Million EUR | 0.0% |
| 2015 FY | -14.52 Million EUR | -6521.05% |
| 2015 Q4 | -8.02 Million EUR | 0.0% |
| 2014 Q4 | -2.63 Million EUR | -199900.0% |
| 2014 FY | -219.36 Thousand EUR | -154.73% |
| 2014 Q1 | -226.50 EUR | 0.0% |
| 2014 Q2 | -453 Thousand EUR | -199900.0% |
| 2014 Q3 | -1318.00 EUR | 99.71% |
| 2013 FY | -86.11 Thousand EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | -533.333% |
| Adocia SA | 1.38 Million EUR | -182.599% |
| Aelis Farma SA | 12.35 Million EUR | 68.328% |
| Biophytis S.A. | -803 Thousand EUR | 587.422% |
| Advicenne S.A. | 1.42 Million EUR | -174.474% |
| genOway Société anonyme | 20.1 Million EUR | 80.528% |
| IntegraGen SA | 5.01 Million EUR | 22.005% |
| Medesis Pharma S.A. | -2.66 Million EUR | 246.88% |
| Neovacs S.A. | 29.31 Thousand EUR | -13251.982% |
| NFL Biosciences SA | -56.06 Thousand EUR | 7081.307% |
| Plant Advanced Technologies SA | 2.15 Million EUR | -81.8% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | 375.772% |
| Sensorion SA | 3.78 Million EUR | -3.33% |
| Theranexus Société Anonyme | -4.63 Million EUR | 184.377% |
| TME Pharma N.V. | -127 Thousand EUR | 3181.89% |
| Valbiotis SA | 2.66 Million EUR | -46.702% |
| TheraVet SA | -530.79 Thousand EUR | 837.383% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | -208.919% |
| DBV Technologies S.A. | 4.15 Million EUR | 5.904% |
| Genfit S.A. | 28.22 Million EUR | 86.132% |
| GeNeuro SA | -293.8 Thousand EUR | 1432.199% |
| Innate Pharma S.A. | -4.12 Million EUR | 194.977% |
| Inventiva S.A. | 17.5 Million EUR | 77.634% |
| MaaT Pharma SA | 1.65 Million EUR | -136.495% |
| MedinCell S.A. | 9.28 Million EUR | 57.86% |
| Nanobiotix S.A. | 36.2 Million EUR | 89.19% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -75.752% |
| Poxel S.A. | 1000.00 EUR | -391300.0% |
| GenSight Biologics S.A. | 3 Million EUR | -30.467% |
| Transgene SA | -28.4 Million EUR | 113.78% |
| Valneva SE | 52.83 Million EUR | 92.592% |